{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T05:08:14Z","timestamp":1781759294705,"version":"3.54.5"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jiac.2022.12.005","type":"journal-article","created":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T02:18:00Z","timestamp":1671416280000},"page":"309-315","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacokinetics of cefmetazole in plasma, peritoneal fluid, peritoneum, and subcutaneous adipose tissue of patients scheduled for lower gastrointestinal surgery: Dosing considerations based on site-specific pharmacodynamic target attainment"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0800-4458","authenticated-orcid":false,"given":"Yuki","family":"Kaiki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Ohge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuro","family":"Ikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3775-989X","authenticated-orcid":false,"given":"Shinnosuke","family":"Uegami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Watadani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9069-463X","authenticated-orcid":false,"given":"Norifumi","family":"Shigemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6107-7170","authenticated-orcid":false,"given":"Toshinori","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1651-0091","authenticated-orcid":false,"given":"Hiroki","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norifumi","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jiac.2022.12.005_bib1","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1128\/AAC.05186-14","article-title":"Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program, 2009 to 2013","volume":"59","author":"Lob","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.jiac.2022.12.005_bib2","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1093\/cid\/ciy768","article-title":"Carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae and the risk of surgical site infection after colorectal surgery: a prospective cohort study","volume":"68","author":"Dubinsky-Pertzov","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.jiac.2022.12.005_bib3","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1128\/AAC.00607-13","article-title":"Correlations of antibiotic use and carbapenem resistance in Enterobacteriaceae","volume":"57","author":"McLaughlin","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.jiac.2022.12.005_bib4","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1473-3099(14)70950-8","article-title":"\u03b2-lactam and \u03b2-lactamase inhibitor combinations in the treatment of extended-spectrum \u03b2-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options?","volume":"15","author":"Harris","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiac.2022.12.005_bib5","author":"Japanese Society of Chemotherapy and Japan Society for Surgical Infection"},{"issue":"4","key":"10.1016\/j.jiac.2022.12.005_bib6","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.diagmicrobio.2015.12.001","article-title":"In vitro activities and detection performances of cefmetazole and flomoxef for extended-spectrum \u03b2-lactamase and plasmid-mediated AmpC \u03b2-lactamase-producing Enterobacteriaceae","volume":"84","author":"Matsumura","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"6","key":"10.1016\/j.jiac.2022.12.005_bib7","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.ijantimicag.2018.08.026","article-title":"Carbapenems and alternative \u03b2-lactams for the treatment of infections due to extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae: what impact on intestinal colonisation resistance?","volume":"52","author":"Woerther","year":"2018","journal-title":"Int J Antimicrob Agents"},{"issue":"9","key":"10.1016\/j.jiac.2022.12.005_bib8","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1128\/AAC.00701-15","article-title":"Multicenter retrospective study of cefmetazole and flomoxef for treatment of extended-spectrum-\u03b2-lactamase-producing Escherichia coli bacteremia","volume":"59","author":"Matsumura","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.jiac.2022.12.005_bib9","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1007\/s11095-021-03140-7","article-title":"Cefmetazole as an alternative to carbapenems against extended-spectrum beta-lactamase-producing Escherichia coli infections based on in Vitro and in Vivo pharmacokinetics\/pharmacodynamics experiments","volume":"38","author":"Takemura","year":"2021","journal-title":"Pharm Res (N Y)"},{"key":"10.1016\/j.jiac.2022.12.005_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40780-016-0071-6","article-title":"Optimal dosage of cefmetazole for intraoperative antimicrobial prophylaxis in patients undergoing surgery for colorectal cancer","volume":"3","author":"Tomizawa","year":"2017","journal-title":"J Pharm Health Care Sci"},{"issue":"1","key":"10.1016\/j.jiac.2022.12.005_bib11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40560-021-00555-7","article-title":"The Japanese clinical practice guidelines for management of sepsis and septic shock 2020 (J-SSCG 2020)","volume":"9","author":"Egi","year":"2021","journal-title":"J Intensive Care"},{"issue":"1\u20132","key":"10.1016\/j.jiac.2022.12.005_bib12","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0021-9673(97)01292-2","article-title":"Quantitative determination of semisynthetic cephamycins in human serum and urine by ion-exchange, reversed-phase and ion-pair chromatography","volume":"812","author":"Garc\u00eda-Gonzalez","year":"1998","journal-title":"J Chromatogr A"},{"issue":"11","key":"10.1016\/j.jiac.2022.12.005_bib13","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1248\/bpb1978.4.879","article-title":"A pharmacokinetic analysis program (MULTI) for microcomputer","volume":"4","author":"Yamaoka","year":"1981","journal-title":"J Pharmacobio-Dyn"},{"key":"10.1016\/j.jiac.2022.12.005_bib14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ijantimicag.2013.08.016","article-title":"Application of pharmacokinetic\/pharmacodynamic modelling and simulation for the prediction of target attainment of ceftobiprole against meticillin-resistant Staphylococcus aureus using minimum inhibitory concentration and time-kill curve based approaches","volume":"43","author":"Barbour","year":"2014","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"10.1016\/j.jiac.2022.12.005_bib15","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jiac.2015.04.015","article-title":"Penetration of piperacillin-tazobactam into human prostate tissue and dosing considerations for prostatitis based on site-specific pharmacokinetics and pharmacodynamics","volume":"21","author":"Kobayashi","year":"2015","journal-title":"J Infect Chemother"},{"issue":"3","key":"10.1016\/j.jiac.2022.12.005_bib16","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ijantimicag.2007.04.012","article-title":"Pharmacokinetic and pharmacodynamic profiling of cefepime in plasma and peritoneal fluid of abdominal surgery patients","volume":"30","author":"Ikawa","year":"2007","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"10.1016\/j.jiac.2022.12.005_bib17","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ijantimicag.2007.06.001","article-title":"Peritoneal penetration and pharmacodynamic exposure of intravenous cefozopran in abdominal surgery patients","volume":"30","author":"Ikawa","year":"2007","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"10.1016\/j.jiac.2022.12.005_bib18","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ijantimicag.2017.03.025","article-title":"Pharmacokinetics of piperacillin-tazobactam in plasma, peritoneal fluid and peritoneum of surgery patients, and dosing considerations based on site-specific pharmacodynamic target attainment","volume":"50","author":"Murao","year":"2017","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"10.1016\/j.jiac.2022.12.005_bib19","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jiac.2021.03.010","article-title":"Change in antimicrobial susceptibility of pathogens isolated from surgical site infections over the past decade in Japanese nation-wide surveillance study","volume":"27","author":"Ueda","year":"2021","journal-title":"J Infect Chemother"},{"issue":"1","key":"10.1016\/j.jiac.2022.12.005_bib20","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/s12879-016-1770-1","article-title":"Cefmetazole for bacteremia caused by ESBL-producing Enterobacteriaceae comparing with carbapenems","volume":"16","author":"Fukuchi","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"8","key":"10.1016\/j.jiac.2022.12.005_bib21","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.jiac.2022.03.024","article-title":"Timing of re-dosing based on population pharmacokinetic-pharmacodynamics target attainment analysis of cefmetazole in subjects undergoing lower gastrointestinal surgery","volume":"28","author":"Komatsu","year":"2022","journal-title":"J Infect Chemother"},{"issue":"4","key":"10.1016\/j.jiac.2022.12.005_bib22","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.surg.2021.10.013","article-title":"Association of serum and fat tissue antibiotic concentrations with surgical site infections in lower gastrointestinal surgery","volume":"171","author":"Takayama","year":"2022","journal-title":"Surgery"},{"issue":"1","key":"10.1016\/j.jiac.2022.12.005_bib23","first-page":"14","article-title":"Peri-incisional and preoperative administration of cefmetazole for the prophylaxis of wound infection after appendicectomy","volume":"71","author":"Garcia Garcia","year":"1986","journal-title":"Int Surg"},{"issue":"12","key":"10.1016\/j.jiac.2022.12.005_bib24","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/BF02482213","article-title":"An additional dose of cefazolin for intraoperative prophylaxis","volume":"29","author":"Ohge","year":"1999","journal-title":"Surg Today"},{"issue":"4","key":"10.1016\/j.jiac.2022.12.005_bib25","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2165\/00003088-199426040-00002","article-title":"Clinical pharmacokinetics of cefotetan","volume":"26","author":"Martin","year":"1994","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.jiac.2022.12.005_bib26","first-page":"750","article-title":"Antibiotic prophylaxis for surgery in morbidly obese patients","volume":"106","author":"Forse","year":"1989","journal-title":"Surgery"},{"issue":"1","key":"10.1016\/j.jiac.2022.12.005_bib27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/j.1875-9114.1991.tb03592.x","article-title":"Cefmetazole sodium: pharmacology, pharmacokinetics, and clinical trials","volume":"11","author":"Schentag","year":"1991","journal-title":"Pharmacotherapy"},{"issue":"5","key":"10.1016\/j.jiac.2022.12.005_bib28","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ijantimicag.2014.11.012","article-title":"In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis producing extended-spectrum \u03b2-lactamases in China","volume":"45","author":"Yang","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2022.12.005_bib29","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1093\/infdis\/jiaa118","article-title":"Optimizing pharmacokinetics-pharmacodynamics of antimicrobial management in patients with sepsis: a review","volume":"222","author":"Phe","year":"2020","journal-title":"J Infect Dis"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X22003282?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X22003282?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:05:07Z","timestamp":1761159907000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X22003282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1341321X22003282"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2022.12.005","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics of cefmetazole in plasma, peritoneal fluid, peritoneum, and subcutaneous adipose tissue of patients scheduled for lower gastrointestinal surgery: Dosing considerations based on site-specific pharmacodynamic target attainment","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2022.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}